Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2522-2531

  Milowsky, Matthew I ^a   Nanus, David M ^a   Kostakoglu, Lale ^a   Vallabhajosula, Shankar ^a   Goldsmith, Stanley J ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; YTTRIUM 90; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; YTTRIUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BONE METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOFT TISSUE METASTASIS; THROMBOCYTE; THROMBOCYTOPENIA; AGED; DISEASE COURSE; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; PROSTATE TUMOR; SCINTISCANNING;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSTATIC NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 4344618391     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.154     Document Type: Article

References (32)

1. Israeli RS, Powell CT, Corr JG, et al: Expression of the prostate-specific membrane antigen. Cancer Res 54:1807-1811, 1994
2. Silver DA, Pellicer I, Fair WR, et al: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81-85, 1997
3. Wright GL Jr, Grob BM, Haley C, et al: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334, 1996
4. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552-558, 1995
5. Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A 93:749-753, 1996
6. Pinto JT, Suffoletto BP, Berzin TM, et al: Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445-1451, 1996
7. Liu H, Moy P, Kim S, et al: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634, 1997
8. Hamilton A, King S, Liu H, et al: A novel humanised antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res 39:440, 1998 (abstr)
9. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927-935, 1987
10. Lopes AD, Davis WL, Rosenstraus MJ, et al: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50:6423-6429, 1990
11. Chang SS, Heston WDW: The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol 7:7-12, 2002
12. Troyer JK, Feng Q, Beckett ML, et al: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29-37, 1995
13. Elgamal AA, Troychak MJ, Murphy GP: ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate 37:261-269, 1998
14. Petronis JD, Regan F, Lin K: Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 23:672-677, 1998
15. Kahn D, Williams RD, Manyak MJ, et al: 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy: The ProstaScint Study Group. J Urol 159:2041-2046, 1998
16. Liu H, Rajasekaran AK, Moy P, et al: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055-4060, 1998
17. Vallabahajosula S, Smith-Jones PM, Navarro V, et al: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate 58:145-155, 2004
18. Bander NH, Nanus D, Goldsmith S, et al: Phase I trial of humanized monoclonal antibody (mAb) to prostate specific membrane antigen/extracellular domain (PSMAext). Proc Am Soc Clin Oncol 19:477a, 2000 (abstr 1872)
19. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60:5237-5243, 2000
20. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Bander NH, Trabulsi E, Kostakoglu L, et al: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170:1717-1721, 2003
23. Wong JYC, Chu DZ, Yamauchi DM, et al: A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 6:3855-3863, 2000
24. Pai-Scherf LH, Carrasquillo JA, Paik C, et al: Imaging and phase I study of 111In- and 90Y-labeled anti-Lewis Y monoclonal antibody B3. Clin Cancer Res 6:1720-1730, 2000
25. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
26. Tempero M, Leichner P, Baranowska-Kortylewicz J, et al: High-dose therapy with 90yttrium-labeled monoclonal antibody CC49: A phase I trial. Clin Cancer Res 6:3095-3102, 2000
27. O'Donnell RT, DeNardo SJ, Yuan A, et al: Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res 7:1561-1568, 2001
28. Kahn D, Austin JC, Maguire RT, et al: A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm 14:99-111, 1999
29. Deb N, Goris M, Trisler K, et al: Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 2:1289-1297, 1996
30. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
31. O'Donnell RT, DeNardo SJ, Miers LA, et al: Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 50:27-37, 2002
32. O'Sullivan JM, McCready VR, Flux G, et al: High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: A phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 86:1715-1720, 2002